Clinical trials: Benign Prostatic Hyperplasia (BPH)
- Condition Benign Prostatic Hyperplasia (BPH)
- Funder type Industry (pharma, biotech, devices)
- Has posted results yes
Benign Prostatic Hyperplasia (BPH)
Waterjet Ablation Therapy for Endoscopic Resection of Prostate Tissue (WATER)
A prospective multicenter randomized blinded study comparing Aquablation of the prostate with the AQUABEAM System and TURP for the treatment of Lower Urinary Tract Symptoms (LUTS).
- Trial name
- WATER (NCT02505919)
- Testing
- AQUABEAM System, Transurethral Resection of the Prostate (TURP)
- Where
- 17 sites in United States, Australia and 2 more
- Volunteers
- 184 people
- Sponsor
- PROCEPT BioRobotics
Benign Prostatic Hyperplasia (BPH)
Waterjet Ablation Therapy for Endoscopic Resection of Prostate Tissue II
Single-arm, interventional pivotal clinical trial collecting patient data from use of the AQUABEAM System, a personalized image-guided waterjet resection system that utilizes a high-velocity saline stream to resect and remove…
- Trial name
- WATERII (NCT03123250)
- Testing
- Aquablation
- Where
- 16 sites in United States, Canada
- Volunteers
- 101 people
- Sponsor
- PROCEPT BioRobotics
Benign Prostatic Hyperplasia (BPH)
To Evaluate the Feasibility, Preliminary Safety and Performance of Rezūm System in BPH Treatment in China
A real world study to evaluate the feasibility, preliminary safety and performance of Rezūm system in BPH treatment in China Rezūm RWS study
- Trial name
- NCT04823221
- Testing
- Rezūm System
- Where
- China
- Volunteers
- 22 people
- Sponsor
- Boston Scientific Corporation
Benign Prostatic Hyperplasia (BPH)
Study of Median Lobe Prostatic UroLift Procedure
The purpose of this study is to evaluate the safety and effectiveness of using UroLift in subjects with a prostatic median lobe enlargement due to benign prostatic hyperplasia (BPH).
- Trial name
- NCT02625545
- Testing
- UroLift System procedure
- Volunteers
- 45 people
- Sponsor
- NeoTract, Inc.
Benign Prostatic Hyperplasia (BPH)
A Study of Tadalafil in Men With Benign Prostatic Hyperplasia
The purpose of this study is to determine whether an experimental drug known as tadalafil given once daily can reduce the symptoms associated with Benign Prostatic Hyperplasia (straining, urinary frequency, feeling like your…
- Trial name
- NCT00970632
- Testing
- Tadalafil 5 mg, Tamsulosin
- Where
- 44 sites in Australia, Austria and 8 more
- Volunteers
- 511 people
- Sponsor
- Eli Lilly and Company
Benign Prostatic Hyperplasia (BPH)
A New Drug for Benign Prostatic Hyperplasia (BPH) Compared With Placebo
A new drug for benign prostatic hyperplasia is compared to placebo for to determine if it is safe and effective. The study lasts approximately 20 weeks.
- Trial name
- NCT00224107
- Testing
- Silodosin
- Where
- 43 sites in United States
- Volunteers
- 461 people
- Sponsor
- Watson Pharmaceuticals